Article: Newer approaches to the treatment of rheumatoid arthritis.
WMJ : official publication of the State Medical Society of Wisconsin
2003 Volume 102, Issue 7, Page(s) 34–37
Abstract: Growing evidence suggests that rheumatoid arthritis should no longer be considered a benign disease. Considerable data suggest that this disease is associated with diminished long-term survival. Other studies have also shown that in patients with ... ...
| Abstract | Growing evidence suggests that rheumatoid arthritis should no longer be considered a benign disease. Considerable data suggest that this disease is associated with diminished long-term survival. Other studies have also shown that in patients with rheumatoid arthritis, bone damage can occur very early in the disease course. Older disease modifying agents for treating rheumatoid arthritis were limited by long-term toxicity. Newer agents, including methotrexate, leflunomide, and the biologic agents etanercept, infliximab, adalimumab, and anakinra have shown long-term efficacy and superior long-term tolerability. Newer approaches to treating this disease have stressed treatment early in the disease course, before irreversible joint damage occurs, using combinations of second line disease modifying agents. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adalimumab ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Drug Therapy, Combination ; Etanercept ; Humans ; Hydroxychloroquine/therapeutic use ; Immunoglobulin G/therapeutic use ; Infliximab ; Isoxazoles/therapeutic use ; Methotrexate/therapeutic use ; Prednisolone/therapeutic use ; Receptors, Tumor Necrosis Factor/therapeutic use | |||||
| Chemical Substances | Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; Immunoglobulin G ; Isoxazoles ; Receptors, Tumor Necrosis Factor ; Hydroxychloroquine (4QWG6N8QKH) ; Prednisolone (9PHQ9Y1OLM) ; Infliximab (B72HH48FLU) ; Adalimumab (FYS6T7F842) ; leflunomide (G162GK9U4W) ; Etanercept (OP401G7OJC) ; Methotrexate (YL5FZ2Y5U1) | |||||
| Language | English | |||||
| Publishing date | 2003 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 441051-8 | |||||
| ISSN | 1098-1861 ; 0043-6542 | |||||
| ISSN | 1098-1861 ; 0043-6542 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 225: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.